Physician profile
Robert C Dennis
NPI 1447252614
$15,450.35
in general payments reported to CMS, 2019-2025
47 companies · $1,903 in 2025
The $1,903 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,894 · 2020: $1,646 · 2021: $2,823 · 2022: $2,025 · 2023: $2,687 · 2024: $2,473 · 2025: $1,903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,055 · Education: $8.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,054.67 |
| Education | $8.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,074.85 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,758.04 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,393.95 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $1,244.87 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $1,175.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,111.31 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $864.26 | 2019-2025 | |
| Esperion Therapeutics, INC. | $758.23 | 2020-2021 | |
| Glaxosmithkline, LLC. | $644.29 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $631.74 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $363.69 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Amgen INC. | $340.27 | 2019-2025 | Otezla, Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company Ltd. | $307.85 | 2022 | |
| Dexcom, INC. | $276.15 | 2021-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $260.62 | 2023-2025 | Cologuard Collection Kit |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dennis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.